Carnitine replacement medicine and supplement compound · Fact sheet
L-carnitine
Also known as Levocarnitine · Carnitor
L-carnitine supports fatty-acid transport and has approved prescription products for defined carnitine-deficiency disorders. That approval does not establish supplement weight loss, bodybuilding or anti-aging benefits.
What is L-carnitine?
The active L-form is levocarnitine. Acetyl-L-carnitine and other derivatives have different study histories.
Prescription oral tablets, oral solutions, intravenous medicines and dietary supplements need formulation-specific interpretation.
Benefits & claims
Interest spans deficiency treatment, exercise and fat metabolism. Correcting a deficiency is different from adding more to a person with adequate status.
What the evidence supports
- Replacement can correct the biochemical and clinical consequences of defined deficiency disorders.
- A normal role in fat transport does not demonstrate greater fat loss from additional carnitine.
- Evidence for one carnitine derivative cannot be transferred to every related supplement.
Research areas
- Primary systemic carnitine deficiency
- Inborn-error-related carnitine deficiency
- Supplement exercise and metabolic research
Dosage & frequency
Product-specific label informationThis adult tablet reference is from Carnitor labeling for defined deficiency disorders; it does not describe supplement enhancement.
Carnitor 330 mg tablets
Adults treated for label-defined primary systemic or inborn-error-related carnitine deficiency
- Amount
- 990 mg per administration
- Frequency
- Two or three times daily depending on clinical response
- Route studied or labeled
- Oral tablets
Clinical response and biochemical monitoring guide adjustment. This partial adult tablet summary omits pediatric, oral-solution and intravenous schedules and is not a complete prescribing guide.
How to read these amounts
An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.
Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences
Formulations, interactions & practical context
- Identity and pharmacology
- The active L-form is levocarnitine. Acetyl-L-carnitine and other derivatives have different study histories.
Formulation differences
- Prescription oral tablets, oral solutions, intravenous medicines and dietary supplements need formulation-specific interpretation.
Interactions & precautions
- The reviewed sources do not establish a comprehensive human interaction profile for this exact substance or combination.
What is still unresolved
- Benefit in people with adequate carnitine status
- Long-term metabolic consequences of supplementation
- Equivalence of different derivatives
Side effects & risks
- Labeling reports gastrointestinal symptoms, body odor and seizures, including worsening in people with pre-existing seizure activity.
- Increased INR has been reported with warfarin; kidney disease and long-term high-dose oral exposure require specific consideration.
This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.
Clinical research
Moderate human evidenceLabel-supported deficiency treatment is established medical use. NIH describes inconsistent or limited evidence for many non-deficiency supplementation claims.
Studies
Separate liver-disease supplementation trial; not evidence for athletic enhancement.
Personal experiences
Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.
No attributable personal accounts were found in the sources reviewed.
Approval status
Carnitor oral labeling covers primary systemic carnitine deficiency and carnitine deficiency from inborn errors of metabolism. This does not approve general fat loss, athletic enhancement or supplement products.
Approved uses
- Carnitor oral products for primary systemic carnitine deficiency and carnitine deficiency due to inborn errors of metabolism.
FDA approved for a specific product and use
Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.
Open questions
- Benefit in people with adequate carnitine status
- Long-term metabolic consequences of supplementation
- Equivalence of different derivatives
Summary
Evidence for one carnitine derivative cannot be transferred to every related supplement.
Sources
Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.
- nihCarnitor tablets prescribing information
NDA labeling for oral levocarnitine; indications, adult tablet amounts, monitoring and adverse reactions.
- nihNIH ODS: carnitine
Formulation differences, adverse effects and limits of supplementation evidence.
- pubmedL-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis--a randomized and controlled clinical trial.
Separate liver-disease supplementation trial; not evidence for athletic enhancement.